NCT04357028

Measles Vaccine in HCW

Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)

• Status: Suspended
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Kasr El Aini Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

Till now, mortality reports among children below 9 years remains extremely low despite that the incidence of death toll is high and exceeding 50,000 patients among older population, One speculation for lower SARS infectivity is that cross-protective antibodies against measles vaccine ( MV). In mice susceptible to measles virus, recombinant MV induced the highest titers of neutralizing antibodies and fully protected immunized animals from intranasal infectious challenge with SARS-CoV, The primary objective of the present study is to determine the benefit of measles vaccine in health care professional to decrease the incidence of COVID-19. We Hypothesized that, measles vaccine may lower the incidence of serologically proven SARS-CoV-2 infection and reported respiratory illness

Conditions

• Covid19

Interventions

Type	Name	Description
DRUG	Measles-Mumps-Rubella Vaccine	Measles mumps Rubella vaccine is a weak attenuated life vaccine
DRUG	Placebos	0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm

Timeline

• Start date: 2020-07-13
• Primary completion: 2020-12-31
• Completion: 2021-01-01
• First posted: 2020-04-22
• Last updated: 2020-12-22

Locations

1 site across 1 country: Egypt